Date: 2015-04-20
Type of information: Services contract
Compound: development and manufacturing services for Kite\'s lead eACT™ clinical development program
Company: NeoStem (USA - NY) Kite Pharma (USA - CA)
Therapeutic area: Technology - Services - Cancer - Oncology
Type agreement: services contract
Action mechanism:
Disease:
Details: * On April 20, 2015, NeoStem, a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced the expansion of manufacturing services under an existing Services Agreement between its wholly-owned subsidiary, PCT, and Kite Pharma, a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer. Under the terms of the original agreement, PCT and its center of excellence for cell therapy process development, engineering and manufacturing, provided development and manufacturing services for Kite\'s lead eACT™ clinical development program. These services included technology transfer, process development, qualification and implementation of the manufacturing process. Under the expanded Services Agreement, Kite will receive these services through increased facilities and personnel at PCT\'s Mountain View, CA location that are contractually dedicated to Kite.
Financial terms:
Latest news:
